MT-103 / Curacle - LARVOL DELTA

Curacle, Shareholder Allocation Paid-in Capital Increase Decision… Expected Value Increase Through Progress in R&D Development of Major Pipelines such as CU06 and CU71 [Google translation] (Hankyung) - "Curacle...held a board meeting on the 16th and decided to increase capital through a public offering of common stock after allocating a total of 28.6 billion won to shareholders. The number of shares to be issued is 7 million, which is approximately 50% of the current number of issued shares...Curacle plans to focus the funds secured through this paid-in capital increase on R&D costs and operating funds for its main pipelines. The main uses are: Clinical phase 2b for retinal disease treatment drug CU06, Clinical phase 1 for Alzheimer's disease treatment drug CU71, and R&D progress for main pipelines such as CU01, MT-101, and MT-103....CU06 is a first-in-class new drug candidate under development as an oral retinal disease treatment, and is preparing to apply for an IND (clinical trial plan) for a phase 2b clinical trial in the second half of this year."

Financing • New P2b trial • Alzheimer's Disease • Diabetic Nephropathy • Retinal Disorders

Mabtics-Curacle, 'MT-101' and 'MT-103' domestic and PCT patent applications [Google translation] (HIT News) - "Mabtics announced on the 4th that it has completed domestic and PCT (Patent Cooperation Treaty) patent applications for antibody treatments 'MT-101' and 'MT-103', which it is jointly developing with Curacle. Through this, it is accelerating global commercialization...According to the company, MT-101 is a Tie2 activating antibody under development as a treatment for acute kidney injury (AKI) and chronic renal failure (CKD)...MT-103 is a dual antibody-based retinal disease treatment that combines a Tie2-activating antibody and an anti-VEGF antibody, and is being developed for indications such as wet macular degeneration and diabetic macular edema."

Patent • Acute Kidney Injury • Chronic Kidney Disease • Diabetic Macular Edema • Macular Degeneration

Curacle, Daesung Pharmtech merger… “High correlation and growth potential” [Google translation] (Medipana) - "According to the public notice on the 6th, the merger will be conducted in the form of a small-scale merger through the issuance of new shares, and the merger date is May 14. In particular, through this merger, Curacle expects to further strengthen its financial soundness while also combining Daesung Pharmtech’s raw pharmaceutical ingredient expertise with Curacle’s R&D capabilities, thereby generating high synergy effects....Ophthalmology is an area where Curacle is developing its core pipelines, such as 'CU06 (oral treatment for retinal diseases)' and 'MT-103 (dual antibody for retinal diseases)', and this merger is expected to enable close collaboration by utilizing networks between new drug development and raw pharmaceutical ingredients businesses in the future."

M&A • Retinal Disorders